50 results about "Glycogen phosphorylase" patented technology

Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.

An application of the pentacyclo-triterpenoid used as the glycogen phosphorylase for preparing the medicines to treat diabetes, ischemic cardiovascular and cerebrovascular diseases, and tumor is disclosed.

The invention relates to a glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.

The invention provides a method for enzymatically synthesizing astragalin. The method comprises the following steps that 1, key enzymes needed in the synthesizing process of astragalin are cloned, expressed and purified, wherein the key enzymes comprise glycogen phosphorylase GP, glucose pyrophosphorylase GalU, flavanone-3-hydroxylase F3H, flavanone synthase FLS1 and flavonoid3-O-glucanotransferase UGT78K2; 2, glycogen Gn is synthesized into glucose-1-phosphoric acid G-1-P under the GP effect; 3, G-1-P is synthesized into uridine diphosphate UDPG under the GalU effect; 4, naringenin NRN is synthesized into dihydro kaempferol DHK under the F3H effect; 5, DHK is synthesized into kaempferol KMF under the FLS1 effect; 6, KMF and UDPG are synthesized into astragalin under the UGT78K2 effect. According to the method, few steps are adopted, the operation condition is mild, few side products are generated, the yield is large, pollution is avoided, and the production cost is remarkably reduced.

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

The invention relates to the field of medicinal chemistry, in particular to a photoaffinity labeling marker probe molecule as well as a preparation method and medical application thereof. The probe molecule can be used for selectively marking glycogen phosphorylase in serum, and then the glycogen phosphorylase can be qualitatively and quantitatively detected, so that the probe molecule can be applied to marking detection on a biochemistry marker, namely, glycogen phosphorylase when diseases such as myocardial infarction, angina, arrhythmia, ischemic sudden cardiac arrest and coronary heart disease occur.

A compound of formula I

wherein

• • W is a bicyclic hetroaryl of the structure

Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound, either alone or in combination with another therapeutic agent.

The invention provides molecular markers of early liver cancer and application of the markers. The molecular markers of early liver cancer comprise amino-acylase-1 (ACY1), sulphite oxidase (SUOX) and glycogen phosphorylase (PYGL). The invention further provides an application of ACY1, SUOX and PYGL as molecular markers of early liver cancer in preparation of liver cancer clinical diagnostic reagents. The invention further provides a liver cancer diagnostic kit, wherein the liver cancer diagnostic kit is characterized by comprising ACY1 antibody, SUOX antibody and PYGL antibody. In the invention, new molecular markers of early liver cancer are discovered and have relatively high detection sensitivity and specificity.

The invention relates to an azo bond contained glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The azo bond contained glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.

The invention relates to a glycogen phosphorylase inhibitor cholic acid derivative containing bio-cleavable dipeptide, a preparation method thereof and a pharmaceutical composition containing the same. The glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.

The invention relates to an agricultural seed treatment agent. The agricultural seed treatment agent consists of the following components in parts by mass: 56 to 60 parts of sodium lignin sulfonate, 58 to 62 parts of borax, 54 to 58 parts of prochloraz, 58 to 62 parts of clothianidin, 54 to 58 parts of chlorothalonil, 58 to 62 parts of antibacterial peptide, 54 to 58 parts of phoxim, 60 to 64 parts of sodium tungstate, 54 to 58 parts of thifluzamide, 58 to 62 parts of indoleacetic acid, 54 to 58 parts of starch dextrin, 58 to 62 parts of glyphosate, 54 to 58 parts of diniconazole, 58 to 62 parts of (hydroxyethylidene) diphosphonic acid, 54 to 58 parts of dimethomorph, 58 to 62 parts of calcium chloride, 54 to 58 parts of purslane extract solution, 58 to 62 parts of polyoxyethylene, 54 to 58 parts of lauryl sodium sulfate, 58 to 62 parts of zinc methyl arsenate, 54 to 58 parts of carbosulfan and 58 to 62 parts of glycogen phosphorylase. The preparation method of the agricultural seed treatment agent is simple, the prepared product has better antibacterial and mold-proof performance, the agricultural seed germination rate is greatly improved and the agricultural seed treatment agent is suitable for use in the agricultural field.

The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

The invention belongs to the technical field of drug synthesis and discloses a glycogen phosphorylase inhibitor and a preparation method and application thereof. The gGlycogen phosphorylase inhibitor has a structural general formula shown as a formula (1) or pharmaceutically-acceptable salt or ester, wherein each of X1, X2, X3 and X4 is a carbon atom connecting group, or one of X1, X2, X3 and X4 is a nitrogen atom connecting group while each of the others is a carbon atom connecting group; R is H, halogen, hydroxyl, cyan, alkyl of C1-6, alkoxy of C1-6, trifluromethyl, vinyl or acetylenyl. The glycogen phosphorylase inhibitor of a novel structure has inhibiting effect on glycogen phosphorylase, is equivalent to PSN-357 in glycogenolysis inhibiting effect on a cell level and can be used for preparing drugs for treating diabetes and complications thereof, hyperlipemia, hypertension and complications thereof, atherosis, obesity and metabolic syndrome.

The invention discloses a germination accelerating processing agent having antibiosis function for Brazilian cherry seeds, which comprises the following components by weight: 100 parts of ethanol, 28-35 parts of isovitamin C sodium salt, 13-17 parts of glycogen phosphorylase, 2-6 parts of citric acid and 0.2-1 part of zinc sulfate. According to the tissue structure, the germination accelerating processing agent having antibiosis function for Brazilian cherry seeds enables cell wall tissue dissociation with pertinency, cell wall of the Brazilian cherry seeds can be softened for disintegration, activity of seeds can not be influenced, shooting rate can reach more than 95%, intrusion of bacteria can be effectively avoided, and seed quality can be ensured.

The invention discloses a near infrared fluorescence detection kit for glycogen phosphorylase isoenzyme BB and application of the near infrared fluorescence detection kit. The near infrared fluorescence detection kit comprises a reagent strip on a backboard, wherein the reagent strip comprises a sample pad, a glass fiber film marked by an immunofluorescence probe, a nitrocellulose membrane coated by the anti-glycogen phosphorylase isoenzyme BB antibody, and absorbent paper. According to the invention, by combining with the near infrared fluorescence detection technology, the detection kit can rapidly and accurately detect the glycogen phosphorylase isoenzyme BB in human whole blood, serum and plasma.

The invention discloses a compound having a structure formula I as shown in the specification, a preparation method and application thereof as well as pharmaceutically acceptable salts or esters of the compound. The compound is a novel cholic acid conjugated pyrrole amide based glycogen phosphorylase inhibitor, can take effect on glycogen phosphorylase of the liver effectively and can function as an optimal medicine for patients with type II diabetes to control blood sugar. The compound can be used for preparing medicines for resisting diabetes and complication thereof, medicines for resisting cardiovascular diseases, medicine for reducing weight and medicines for treating metabolic syndromes.

The invention discloses a medlar seed tissue decomposition agent which comprises the following components by weight: 100 parts of ethanol, 10-15 parts of triethylamine, 2-5 parts of cholinesterase, 2-5 parts of glycogen phosphorylase, 0.5-1 part of calcium chloride, and 0.02-0.6 part of zinc sulfate. The medlar seed tissue decomposition agent provided in the invention performs specific cell wall tissue dissociation according to the structure and tissue of medlar seed cell walls, realizes thorough decomposition of medlar seed cell walls under a common mechanical wall breaking condition, and thus realizes complete and rapid release of effective components in cells.